- We strive to ensure that all patients in Poland, especially those with lung cancer, for whom the performance of molecular tests is crucial, have equal access to such services, so that it is not the case that only some patients have treatment in accordance with current medical knowledge, and the rest do not. This is not why we are trying to get modern therapies into the drug program, so that patients don't benefit from them. Very few people benefit from innovative therapies, precisely because molecular testing is not done. It's also increasingly the case that patients have tests ordered, but doctors don't wait for the results, they just give chemotherapy," said Aleksandra Wilk, director of the Lung Cancer Section at the To Się Leczy Foundation.
- We have a strange paradox in which there are tools for genetic testing and there are targeted therapies, and the problem is that the two cannot meet. The patient, instead of benefiting from modern therapies, is held back at some point. He can't take advantage of modern therapies because he can't do genetic testing. One would have to wonder why this problem is there and why access to testing varies so much regionally," added Dorota Korycinska, CEO of the National F...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
